04.17.24
CordenPharma, a global CDMO in the manufacturing of drug substance (APIs) complex modalities (such as peptides, oligos and lipids) and injectable drug products, and GENEPEP, a French CRO specializing in the design, chemical synthesis, and optimization of peptides, have celebrated one year of their collaboration.
The partnership, signed in 2023, supports biotech companies with the development, discovery, and manufacturing of peptides for early clinical phase, leveraging CordenPharma’s cGMP manufacturing capacities, regulatory know-how and market access, and GENEPEP’s discovery and drug development expertise.
Under the agreement, GENEPEP provides services for research and discovery activities, as well as support for initial Investigational New Drug (IND) application packages, including selection of lead and alternative compounds for discovery purpose, research-grade samples including testing reports, process familiarization, and development. In addition, they supply gram peptide manufacturing samples representative of tox quality, ensuring a smooth transition to the CordenPharma Frankfurt site for early clinical GMP manufacturing, along with access to their global sales and marketing organization.
Dr. Stéphane Varray, CordenPharma’s Global Peptide Platform Director, said, “With our new early clinical GMP peptide manufacturing investment in Frankfurt and the strategic partnership with GENEPEP, we are proud to strengthen our peptide offering for biotech and pharma customers in early discovery to First-In-Human clinical stage. In the past 12 months, we have demonstrated together how this collaboration has simplified and expedited the critical milestones of lead development and validation in a clinical setting, bringing added value for our global customers.”
Dr. Karine Puget, founder and CEO of GENEPEP, said, “Thanks to this collaboration between GENEPEP & CordenPharma, customers of both companies now have access to collaborative and specialized teams tailored to meet the needs of each of the Research and Development phases of their project.”
The partnership, signed in 2023, supports biotech companies with the development, discovery, and manufacturing of peptides for early clinical phase, leveraging CordenPharma’s cGMP manufacturing capacities, regulatory know-how and market access, and GENEPEP’s discovery and drug development expertise.
Under the agreement, GENEPEP provides services for research and discovery activities, as well as support for initial Investigational New Drug (IND) application packages, including selection of lead and alternative compounds for discovery purpose, research-grade samples including testing reports, process familiarization, and development. In addition, they supply gram peptide manufacturing samples representative of tox quality, ensuring a smooth transition to the CordenPharma Frankfurt site for early clinical GMP manufacturing, along with access to their global sales and marketing organization.
Dr. Stéphane Varray, CordenPharma’s Global Peptide Platform Director, said, “With our new early clinical GMP peptide manufacturing investment in Frankfurt and the strategic partnership with GENEPEP, we are proud to strengthen our peptide offering for biotech and pharma customers in early discovery to First-In-Human clinical stage. In the past 12 months, we have demonstrated together how this collaboration has simplified and expedited the critical milestones of lead development and validation in a clinical setting, bringing added value for our global customers.”
Dr. Karine Puget, founder and CEO of GENEPEP, said, “Thanks to this collaboration between GENEPEP & CordenPharma, customers of both companies now have access to collaborative and specialized teams tailored to meet the needs of each of the Research and Development phases of their project.”
